Liqing Kang^1*, Jinfeng Ma^2*, Xiaoyan Lou^1*, Xiaowen Tang^2*, Shengli Xue^2*, Suning Chen^2*, Huiying Qiu^3*, Miao Miao^2*, Yue Han^2*, Ying Wang^2*, Aining Sun^2*, Haiping Dai^2*, Yang Xu, M.D.^4*, Limin Li^5*, Shengjin Fan^5*, Chongsheng Qian^2*, Wenjie Gong^2*, Mingzhu Xu^2*, Haixia Zhou^2*, Zhen Yao^2*, Wei Wang^1*, Minghao Li^1*, Nan Xu^1*, Zhou Yu^1*, Depei Wu^2,6 and Lei Yu^1*

¹Shanghai Unicar-Therapy Bio-Medicine Technology Co.,Ltd, Shanghai, China
²The First Affiliated Hospital of Soochow University, Suzhou, China
³Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China
⁴National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China
⁵Department of Hematology, The First Affiliated Hospital of Harbin Medical University，The Institute of The Hematology and Oncology of Heilongjiang Province, Harbin, China
⁶National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, Suzhou, China

Robert Weinkove, PhD^1,2*, Philip George, MBBS^1,2*, Robert Fyfe, MBBS^1,2*, Nathaniel Dasyam, PhD^1*, Yasmin Nouri, PhD^1,3*, Tess Ostapowicz^1,4*, Stefan Mullins, MB BCh^1,2*, Brigitta Mester, PhD^1*, Giulia Giunti, PhD^5,6*, Catherine M. Bollard, MD⁷, Travis Perera, MBBS^2*, Hayden Jina, MD^2*, Alwyn D'Souza, MBBS^2*, Le Qin, PhD^8*, David S. Ritchie, MD, PhD, FRACP, FRCPA⁹, Chris M.A. Frampton, PhD^10*, Rachel Perret, PhD^1*, Peng Li, PhD^8,11* and Ian Hermans, PhD^1*

¹Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand
²Te Rerenga Ora Wellington Blood & Cancer Centre, Te Whatu Ora Health New Zealand Capital Coast & Hutt Valley, Wellington, New Zealand
³Division of Immunology, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
⁴Clinical Trials Unit, Te Whatu Ora Health New Zealand Capital Coast & Hutt Valley, Wellington, New Zealand
⁵Clinical Human Immunology Laboratory, Malaghan Institute of Medical Research, Wellington, New Zealand
⁶BioOra, Wellington, New Zealand
⁷Children’s National Hospital, Washington, DC
⁸Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
⁹Department of Medicine, The University of Melbourne, Parkville, VIC, Australia
¹⁰Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand
¹¹Wellington Zhaotai Therapies Limited, Wellington, New Zealand

Mingming Zhang^1,2,3,4*, Yongxian Hu^1,2,3,4*, Guoqing Wei^2,3,4,5*, Shan Fu^1*, Jingjing Feng^1*, Ruimin Hong^1*, Alex H. Chang^6* and He Huang^2,3,4,5*

¹Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
²Institute of Hematology, Zhejiang University, Hangzhou, China
³Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy, Hangzhou, China
⁴Liangzhu Laboratory, Zhejiang University Medical Center, Hangzhou, China
⁵Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
⁶Shanghai YaKe Biotechnology Ltd, Shanghai, China

Jae H. Park, MD¹, Maria Lia Palomba, MD², Sean M. Devlin, PhD^3*, Yannis K. Valtis, MD¹, Devanjan S Sikder^4*, Brigitte Senechal^4*, Xiuyan Wang, PhD^4*, Elizabeth Cathcart^5*, Kelly Liotta^6*, Alina Yu^6*, Kelsey Stocker^6*, Honglei Zhang^7*, Heiko Schoder, MD^8*, Doris Leithner, MD^9*, Jia Li^10*, Leopold Sellner^11*, Jorge Mansilla-Soto^1*, Isabelle Riviere^11* and Michel Sadelain, MD PhD¹²

¹Memorial Sloan Kettering Cancer Center, New York, NY
²Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
³Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer Center, New York, NY
⁵Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
⁶Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York
⁷Memorial Sloan Kettering Cancer Center, New York
⁸Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York
⁹Molecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁰Takeda Development Center Americas, Inc., Cambridge, MA
¹¹Takeda Development Center Americas, Inc., Lexington, MA
¹²Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY

Pierre Sesques^1*, Roch Houot, MD, PhD^2*, Yassine Al Tabaa, MD, PhD, PharmD^3*, Fabien Le Bras, MD^4*, Loic Ysebaert, MD, PhD^5*, Fabrice Jardin, MD PhD^6*, Choquet Sylvain^7*, Jacques-Olivier Bay, MD, PhD^8*, Francois Xavier Gros, MD^9*, Franck Morschhauser, MD PhD¹⁰, Olivier Casasnovas^11*, Thomas Gastinne, MD^12*, Catherine Thieblemont, MD^13*, Magalie Joris, MD^14*, Laure Ricard, MD^15*, Caroline Regny^16*, Laurianne Drieu La Rochelle^17*, Pierre Feugier^18*, Ambroise Marcais, MD^19*, Karin Tarte, PhD, PharmD^20*, Camille Laurent, MD, PhD^21* and Guillaume Cartron, MD, Ph-D^22*

¹CHU LYON SUD, PIERRE BENITE CEDEX, France
²Clinical Hematology, INSERM U1236, EFS, Hopital Pontchaillou, Rennes University Hospital, Rennes, France
³scintidoc, Montpellier, FRA
⁴Clinical Hematology, Henri-Mondor Hospital, Assistance Publique - Hôpitaux de Paris, Paris, FRA
⁵Hematology Department, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
⁶Centre Henri-Becquerel and University of Rouen, Rouen, France
⁷Hopital de la Pitié Salpetrière, APHP, Paris, FRA
⁸Service d’hématologie, CHU Clermont-Ferrand, Clermont-Ferrand, France
⁹CHU BORDEAUX, Merignac, FRA
¹⁰Hematology Department, Centre Hospitalier Régional Universitaire de Lille, Lille, AL, France
¹¹CHU Dijon, Dijon, FRA
¹²CHU de Nantes, Nantes, France
¹³Hematology Department, Hôpital Saint-Louis, Paris, France
¹⁴Service d’Hématologie Clinique, Centre Hospitalier Universitaire Amiens-Picardie, Amiens, FRA
¹⁵APHP ST ANTOINE, PARIS, France
¹⁶CHU GRENOBLE ALPES, GRENOBLE, France
¹⁷CHU TOURS, Tours, FRA
¹⁸Henri Poincaré University, Vandoeuvre Les Nancy, FRA
¹⁹Hôpital Necker, AP-HP, PARIS, France
²⁰CHU RENNES PONCHAILLOU, Rennes, FRA
²¹Institut Universitaire du Cancer , Oncopole, Toulouse, France
²²Centre Hospitalier Universitaire de Montpellier, Montpellier, France

Julio C. Chavez, MD¹, Michael Dickinson, MBBS, D. Med Sci, FRACP, FRCPA², Javier L. Munoz³, Matthew L. Ulrickson, MD⁴, Catherine Thieblemont, MD^5*, Olalekan O. Oluwole, MBBS⁶, Alex F. Herrera, MD⁷, Chaitra S Ujjani, MD⁸, Yi Lin, MD, PhD⁹, Peter A. Riedell, MD¹⁰, Natasha K. Kekre, MD, MPH, FRCPC^11*, Sven de Vos, MD, PhD^12*, Christine Lui, MS^13*, Jacob Wulff, DrPH^13*, Chad M. Williams, PhD^13*, Weixin Peng, MS^13*, Ioana Kloos, MD^13*, Hairong Xu, MD, PhD^13* and Sattva S. Neelapu, MD¹⁴

¹Moffitt Cancer Center, Tampa, FL
²Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia
³Banner MD Anderson Cancer Center, Phoenix, AZ
⁴Banner MD Anderson Cancer Center, Gilbert, AZ
⁵Service d'hémato-oncologie, Hôpital Saint-Louis, Paris, France
⁶Vanderbilt-Ingram Cancer Center, Nashville, TN
⁷City of Hope, Duarte, CA
⁸Clinical Research Division, Fred Hutch Cancer Center; and Division of Oncology, University of Washington, Seattle, WA
⁹Mayo Clinic Cancer Center, Rochester, MN
¹⁰David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL
¹¹Department of Medicine, The Ottawa Hospital, Ottawa, ON, Canada
¹²David Geffen School of Med. at UCLA, Los Angeles, CA
¹³Kite, a Gilead Company, Santa Monica, CA
¹⁴Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX